MorphoSys terminates its merger talks with British Biotech
Munich-based biotechnology company MorphoSys has ended merger talks with British Biotech.
Munich-based biotechnology company MorphoSys has ended merger talks with British Biotech.
MorphoSys also updated its guidance regarding strategic equity-based partnerships, and does not expect such a transaction to be completed in the current calendar year. MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which help accelerate drug discovery and target characterisation.